Alector, Inc.

NasdaqGS:ALEC Voorraadrapport

Marktkapitalisatie: US$488.6m

Alector Beheer

Beheer criteriumcontroles 2/4

Alector's CEO is Arnon Rosenthal, appointed in Jan 2013, has a tenure of 11.83 years. total yearly compensation is $4.26M, comprised of 15.4% salary and 84.6% bonuses, including company stock and options. directly owns 5.54% of the company’s shares, worth $27.05M. The average tenure of the management team and the board of directors is 2.8 years and 5.7 years respectively.

Belangrijke informatie

Arnon Rosenthal

Algemeen directeur

US$4.3m

Totale compensatie

Percentage CEO-salaris15.4%
Dienstverband CEO11.8yrs
Eigendom CEO5.5%
Management gemiddelde ambtstermijn2.8yrs
Gemiddelde ambtstermijn bestuur5.7yrs

Recente managementupdates

Recent updates

Alector, Inc.'s (NASDAQ:ALEC) Business And Shares Still Trailing The Industry

Oct 24
Alector, Inc.'s (NASDAQ:ALEC) Business And Shares Still Trailing The Industry

We Think Alector (NASDAQ:ALEC) Needs To Drive Business Growth Carefully

Sep 26
We Think Alector (NASDAQ:ALEC) Needs To Drive Business Growth Carefully

Alector, Inc.'s (NASDAQ:ALEC) Price Is Right But Growth Is Lacking

Jul 11
Alector, Inc.'s (NASDAQ:ALEC) Price Is Right But Growth Is Lacking

Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 11
Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results

Mar 01
Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results

The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 27%

Jan 19
The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 27%

Alector: Good Data, Huge Cash, No Near Term Catalyst

Jan 16

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Sep 25
Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Jun 27
Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Analysts Are Betting On Alector, Inc. (NASDAQ:ALEC) With A Big Upgrade This Week

Mar 02
Analysts Are Betting On Alector, Inc. (NASDAQ:ALEC) With A Big Upgrade This Week

Alector (NASDAQ:ALEC) Is In A Good Position To Deliver On Growth Plans

Jan 16
Alector (NASDAQ:ALEC) Is In A Good Position To Deliver On Growth Plans

Alector: Advancement Of Third Alzheimer's Drug Brings About Huge Potential

Oct 04

AbbVie ends partnership with Alector for Alzheimer’s candidate

Jul 08

Alector: Potential In Neurology And Cancer Treatments

Jun 14

Need To Know: The Consensus Just Cut Its Alector, Inc. (NASDAQ:ALEC) Estimates For 2022

May 18
Need To Know: The Consensus Just Cut Its Alector, Inc. (NASDAQ:ALEC) Estimates For 2022

Alector: Expect Phase 3 Data Next Year

Apr 16

These Analysts Just Made An Downgrade To Their Alector, Inc. (NASDAQ:ALEC) EPS Forecasts

Feb 27
These Analysts Just Made An Downgrade To Their Alector, Inc. (NASDAQ:ALEC) EPS Forecasts

Alector, Inc: A Newer Biotech Company With Big Potential

Jan 26

Alector: The GSK Deal Is A Major Value Add

Oct 29

Analyse CEO-vergoeding

Hoe is Arnon Rosenthal's beloning veranderd ten opzichte van Alector's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$161m

Mar 31 2024n/an/a

-US$121m

Dec 31 2023US$4mUS$654k

-US$130m

Sep 30 2023n/an/a

-US$141m

Jun 30 2023n/an/a

-US$143m

Mar 31 2023n/an/a

-US$135m

Dec 31 2022US$4mUS$621k

-US$133m

Sep 30 2022n/an/a

-US$136m

Jun 30 2022n/an/a

US$36m

Mar 31 2022n/an/a

-US$29m

Dec 31 2021US$10mUS$575k

-US$36m

Sep 30 2021n/an/a

-US$33m

Jun 30 2021n/an/a

-US$212m

Mar 31 2021n/an/a

-US$202m

Dec 31 2020US$4mUS$554k

-US$190m

Sep 30 2020n/an/a

-US$169m

Jun 30 2020n/an/a

-US$148m

Mar 31 2020n/an/a

-US$127m

Dec 31 2019US$7mUS$525k

-US$105m

Sep 30 2019n/an/a

-US$92m

Jun 30 2019n/an/a

-US$76m

Mar 31 2019n/an/a

-US$62m

Dec 31 2018US$5mUS$397k

-US$52m

Sep 30 2018n/an/a

-US$45m

Jun 30 2018n/an/a

-US$39m

Mar 31 2018n/an/a

-US$35m

Dec 31 2017US$3mUS$370k

-US$32m

Compensatie versus markt: Arnon's total compensation ($USD4.26M) is above average for companies of similar size in the US market ($USD2.42M).

Compensatie versus inkomsten: Arnon's compensation has increased whilst the company is unprofitable.

CEO

Arnon Rosenthal (68 yo)

11.8yrs

Tenure

US$4,255,007

Compensatie

Dr. Arnon Rosenthal, Ph D., Co-Founded Annexon in 2013 and serves as its Chief Executive Officer and Director since 2013 and served as its President since 2013. He served as Chief Scientific Officer of Ale...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Arnon Rosenthal
Co-Founder11.8yrsUS$4.26m5.54%
$ 27.1m
Saraswati Kenkare-Mitra
President and Head of Research & Development2.9yrsUS$2.61m0.083%
$ 403.3k
Marc Grasso
CFO, Principal Financial Officer & Principal Accounting Officer2.8yrsUS$1.72m0.035%
$ 170.0k
Gary Romano
Chief Medical Officer2.5yrsUS$1.62m0.078%
$ 383.4k
Katie Hogan
Senior Director of Corporate Communication & Investor Relationsno datageen gegevensgeen gegevens
Danielle Pasqualone
General Counsel2.8yrsgeen gegevensgeen gegevens
Clare Hunt
Chief People Officerno datageen gegevensgeen gegevens
Kristina Cutter
Chief Regulatoryno datageen gegevensgeen gegevens
Virginia DeJesus-Rueff
Chief of Staff & Head of Strategy2.8yrsgeen gegevensgeen gegevens
Norah Conway
Senior Vice President of Portfolio & Program Management2.8yrsgeen gegevensgeen gegevens
Neil Berkley
Chief Business Officerless than a yeargeen gegevensgeen gegevens

2.8yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: ALEC's management team is considered experienced (2.8 years average tenure).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Arnon Rosenthal
Co-Founder11.8yrsUS$4.26m5.54%
$ 27.1m
Louis Lavigne
Independent Chairperson of the Board6.1yrsUS$355.07k0.037%
$ 179.2k
Richard Scheller
Director & Member of Scientific Advisory Board6.1yrsUS$509.13k0%
$ 0
Thomas Sudhof
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Stephen Hauser
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
David Wehner
Independent Director6.1yrsUS$324.71k0.083%
$ 403.3k
Adam Boxer
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Paula Hammond
Independent Director4.7yrsUS$318.92k0.026%
$ 126.5k
Kristine Yaffe
Independent Director5.3yrsUS$318.12k0.034%
$ 164.2k
Michael Heneka
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Martin Kampmann
Member of Scientific Advisory Board2.8yrsgeen gegevensgeen gegevens
Elizabeth Garofalo
Independent Director3.2yrsUS$322.27k0.027%
$ 131.8k

5.7yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: ALEC's board of directors are considered experienced (5.7 years average tenure).